FDA requires warnings for use of Sovaldi ( sofosbuvir) or Harvoni (sofosbuvir plus ledipasvir) with amiodarone- Gilead
The FDA has approved changes to the "Warning and Precautions," "Adverse Reactions" and "Drug Interactions" sections of Sovaldi's and Harvoni's labeling to alert prescribers and patients about serious risk of bradycardia when combining the drugs with amiodarone and other DAAs.( direct acting anti virals).The mechanism of the potential interaction between amiodarone and Harvoni, or Sovaldi in combination with another DAA (direct antiviral agent) is unknown.
The FDA said it is recommended that patients who need amiodarone and Sovaldi and amiodarone be monitored in an inpatient setting for the first 48 hours, followed by daily outpatient or self-monitoring of their heart rate for at least the first two weeks of treatment. It said that because amiodarone has a "long half-life," patients who have just gone off of amiodarone ahead of starting Harvoni or Sovaldi along with a DAA should also be monitored.
Related news and insights
Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
Merck KGaA, a leading science and technology company, announced that its two Phase III EVOLUTION clinical trials (evolution RMS 1 and evolution RMS 2) investigating the efficacy and safety of evobrutinib did not meet their primary endpoints of reducing annualized relapse rates (ARR) in people with relapsing multiple sclerosis (RMS) compared to oral teriflunomide (Aubagio) (0.11 vs. 0.11 in evolution RMS 1 and 0.15 for evobrutinib vs. 0.14 for teriflunomide in evolution RMS 2, p=NS in both trials)